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Perillae fructus (perilla seed) is a traditional medicinal herb used to treat bronchial asthma in
Oriental medical clinics. ST36 is one of the most widely used acupuncture points, particularly
for immune system regulation. Injection of an herbal extract into an acupuncture point (herbal
acupuncture) is a therapeutic technique combining both acupuncture and herbal treatment.
Perillae fructus extract was injected subcutaneously (Perillae fructus herbal acupuncture;
PF-HA) at acupoint ST36 of OVA-induced asthmatic mice. The lung weight, bronchoalveolar
fluid (BALF) cell count, the number of CCR3+, CD11b+, CD4+ and CD3e+/CD69+ cells
in the lung, and the level of IgE, IL-4, IL-5 and IL-13 in BALF and serum were then measured.
RT-PCR was used to measure the mRNA expression of IL-4, IL-5, IL-13 and TNF-a in the
lung. Lung sections were analyzed histologically. PF-HA significantly reduced lung weight,
the number of inflammatory cells in the lung and BALF, the levels of IgE and Th2 cytokines in
BALF and serum, mRNA expression of Th2 cytokines in the lung, and pathological changes
in lung tissue. Our results suggest that PF-HA may have an anti-inflammatory and immune-
regulatory effect on bronchial allergic asthma by restoring the Th1/Th2 imbalance in the
immune system and suppressing eosinophilic inflammation in airways.
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Introduction
Asthma is a heterogeneous disease that is broadly defined
as a clinical syndrome characterized by altered lung
function, peribronchial inflammation and airway respon-
siveness. It is generally regarded as a T-cell mediated
disease that leads to an imbalance of Th1 and Th2
activity (1–3).
Acupuncture has been used to treat various diseases in
Asia for thousands of years and several studies have
demonstrated that acupuncture is an effective treatment
for asthma (4–7). To treat immune diseases, including
asthma, acupuncture points that can boost the vital
energy and regulate the immune system are used. ST36 is
one of the most commonly used acupuncture points
to tonify the vital energy and regulate the immune
system (8,9).
Perillae fructus (perilla seed, PF) is a traditional
medicinal herb that has been used to treat respiratory
diseases. Based on Oriental medical theory, PF enters the
lung meridian, arrests coughing and wheezing with
copious phlegm, and treats exhalation difficulties and
stiffness in the chest (10). The leaves of perilla (Perilla
frutescens) have shown a suppressive effect on type 1
allergies (11). However, perilla seed has not yet been
investigated for use on allergic diseases.
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properly cited.Herbal acupuncture is a traditional Oriental therapeutic
technique that combines acupuncture with herbal treat-
ment. This technique involves injecting an herbal extract
into certain acupuncture points, according to Oriental
medical theory. We hypothesized that combining the
immune-strengthening function of ST36 and respiratory
disease-treating activity of PF would have a synergistic
effect on allergic bronchial asthma.
To investigate perillae fructus herbal acupuncture
(PF-HA) for allergic bronchial asthma, we used an
OVA-induced asthmatic mouse model.
Methods
Medicinal Substance and Herbal-Acupuncture Solution
Dried PF (5g) was washed with an ultrasonic cleaner
(BRANSON, USA) and ground using a pulverizer. The
powder was transferred to a flask containing 500ml of
distilled water, mixed for 3h at 37 C in a shaking
incubator, filtered through 3MM Whatman filter paper
and concentrated using a rotary evaporator. Sequentially,
30ml of 95, 85 and 75% ethanol were then added to the
extract, which was maintained at room temperature.
After filtering out the sediment, the filtrate was con-
densed to 20g. This PF extract was diluted with
phosphate buffered saline (PBS) to a total volume of
2l, and the pH was adjusted to 7.0.
OVA-Induced Asthmatic Mouse Model
Five-week-old male C57BL/6 mice were purchased from
Daehan Biolink (Chungbuk, Ochang, Korea). The mice
were maintained under conventional conditions at a
constant temperature (22 2 C), humidity and ventila-
tion, on a 12h light/dark cycle. Mice had access to water
and food ad libitum. Chicken egg albumin (OVA;
500mg/ml; Sigma, USA) in PBS was mixed with an
equal volume of 10% (w/v) aluminum potassium sulfate
(alum; Sigma) in distilled water and adjusted to pH 6.5
using 10N NaOH. The solution was then incubated
for 60min at room temperature. After centrifugation at
750 g for 5min, the OVA/alum pellet was resuspended
to the original volume in distilled water. The experi-
mental animals were sensitized by intra-peritoneal
injections of OVA/alum (500mg/ml) in the amounts of
200ml on day 0 and 100ml on days 7 and 14. The mice
were challenged with an intra-tracheal injection of 100ml
OVA/alum (500mg/ml) on day 21, and underwent an
aerosol challenge with OVA/alum (2.5mg/ml for 4 weeks
from week 4 to week 8, and 5mg/ml for 4 weeks from
week 8 to week 12) for 30min per day, 3 times a week
using an air compressor (Tamiya, Japan; 12; Fig. 1).
Experimental Groups and Treatments
The mice were divided into six groups (ten mice per
group): normal, normal-PF-HA, OVA-control, OVA-
needle prick (OVA-NP), OVA-saline and OVA-PF-HA
group. All animals except those in the normal and
normal-PF-HA groups underwent OVA exposure. The
mice in the OVA-NP group were given a single needle
prick (subcutaneously with an empty 1-mL syringe
needle). The mice in the OVA-saline group were injected
with saline (100ml) and the mice in the normal-PF-HA
and OVA-PF-HA groups were injected subcutaneously
with PF extract (100ml) at ST36, alternating between left
and right.
NP and PF-HA treatments were conducted for 8 weeks,
three times per week (Fig. 1), using a 1ml injection
syringe. ST36 is located on the stomach meridian,
longitudinally three cun below the knee joint, transversely
in the middle of the tibialis anterior muscle. For better
point location on the mice, we placed a rubber band
along a ruler and marked it at 0, 3 and 16cm. The rubber
band was then set on the mouse hind limb, with the 0cm
mark at ST35 (located at the lower border of the patellar,
in the depression lateral to the patellar ligament; 8) and
the 16cm mark at ST41 (located on the dorsum of
the foot, at the midpoint of the transverse crease of the
ankle joint, in the depression between the m. extensor
digitorum longus and hallucis longus tendons; 8). The
point corresponding to the 3cm mark on the rubber band
was determined to be ST36. While the needle prick, saline
injections or PF extract injections were delivered, the
mice were restrained by hand.
Bronchoalveolar-lavage Fluid (BALF)
The mouse trachea was cannulated and the lungs were
washed 3 times with 1ml of DMEM. The bronchoalveolar
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Figure 1. OVA-induced asthmatic mouse model.
80 Anti-asthmatic effect of PF-HAlavage fluid (BALF) was immediately centrifuged and the
supernatant was collected for cytokine measurements.
Cell pellets were resuspended and cytocentrifuged for
total leucocyte measurement after red blood cell lysis.
Photomicrographs
The total BALF was collected and washed with PBS.
The BALF cells were cytocentrifuged onto slides using
a Cytospin and stained with a Hemacolor rapid staining
set (Merck KGaA, Germany). Eosinophils were counted
using a bright field microscope ( 400; Nikon, Japan).
Histological Analysis
The lungs were removed, washed with PBS and infused
with 10% formalin in PBS for fixation. The lung tissue
was sectioned and stained with Masson’s trichrome
reagent.
Fluorescence-Activated Cell Sorter (FACS) Analysis
The lungs were removed and minced in RPMI1640.
Lung cells were harvested in a shaking incubator and
reacted with either PE or FITC-conjugated antibodies
(Pharmingen, USA) for 1h on ice. After washing, the
cells were analyzed using a Flow cytometer (Becton
Dickinson, USA). One sample from each group was
analyzed as a representative.
Enzyme-Linked Immunosorbent Assay (ELISA) Analysis
Each cytokine was evaluated with an ELISA kit
(Biosource, USA) according to the manufacturer’s
protocol.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
After the lung tissue was homogenized, the total RNA
was extracted using RNAzolB (Tel-Test, USA). Three mg
of the total RNA were denatured for 10min at 75 C and
mixed with 2.5ml of 10mM dNTPs, 1ml of random
sequence hexanucleotides (25 pmole/25ml), 0.5ml of RNA
inhibitor, 1ml of 100mM DTT, 4mlo f5   RT buffer
(250mM Tris-Cl, pH 8.3, 375mM KCl, 15mM MgCl2)
and 1ml of M-MLV RT (200 U/ml). The synthesis of first-
strand cDNA was carried out for 1h in a 37 C water
bath. PCR amplification was carried out in 2ml of PCR
buffer (10mM Tris-HCl, pH 8.3), 1.6ml of dNTP (2.5M),
1ml of sense primer (20 pmole/ml) and antisense primer
(20 pmole/ml), 0.15ml of Taq polymerase, 13.25mlo f
distilled water and 2ml of each cDNA sample. One PCR
cycle (29 cycles total) consisted of denaturation at 94 C
for 1min, annealing at 57 C for 1min and polymeriza-
tion at 72 C for 1min. The RT-PCR products were
electrophoresed on a 1.2% agarose gel. The primer
sequences were as follows: mouse IL-4, 50-AGCCATAT
CCACGGATGCGA C-30 and 50-GCATGGTGGCTCA
GTACTACG-30; IL-5, 50-GCTCCTTCAGGAATCTGT
TC-30 and 50-GGCTCATGTACTTTCATGAG-30; IL-13,
50-GCCGGGATGGGCATTCCACGTGTG-30 and 50-G
GACGCCAAGGTCAAGAACAGTTG-30; TNF-a,5 0-A
CGGCTGACTGTCAGATTGTTAG -30 and 50-GTCAC
AGTTTTCAGCTGTATAGGG-30; b-actin, 50-TGGAA
TCCTGATCCATGAAC-30 and 50-TAAAACGCAGC
TCAGTAGTCCG-30.
Statistical Analyses
Statistical analyses were performed using analysis of
variance (ANOVA) multiple t-tests (JAVA, Bonferroni
Ver II). The results are expressed as a mean SEM.
Results were considered statistically significant
at P 0.05.
Results
Lung Weight and BALF Cell Counts Reduced
The lung weight of the OVA-control group was
significantly higher than that of the normal group.
In contrast, the lung weight of the OVA-PF-HA group
was lower than those of the OVA-control and OVA-NP
groups. The number of leucocytes and eosinophils in the
BALF were significantly higher in the OVA-control
group than in the normal group. In contrast, those of
the OVA-PF-HA group were significantly lower than the
OVA-control and OVA-NP groups (Table 1).
Eosinophil Recruitment and Collagen Accumulation
Reduced in the Lung
The photomicrographs show that PF-HA reduced eosi-
nophils in BALF (Fig. 2). Histological analysis of mouse
lungs in the OVA-control group showed a large increase
in eosinophil recruitment in the airways and collagen
accumulation compared to the normal group. The lungs
of mice treated with PF-HA had significantly fewer
eosinophils and less collagen accumulation than in the
OVA-control, OVA-NP and OVA-saline groups (Fig. 3).
Inflammatory Immune Cell Populations Reduced
in the Lung
The population of CCR3+ cells in the lungs of the
OVA-control group was significantly higher than in the
normal group. On the other hand, CCR3+ cells were
significantly lower in the PF-HA group than in the OVA-
control, OVA-NP and OVA-saline groups (Fig. 4). The
number of CD11b+, CD4+ and CD3e+/CD69+ cells
eCAM 2010;7(1) 81Table 1. Effect of PF-HA at ST36 on lung weight and BALF cell counts
Normal Normal-PF-HA OVA-Control OVA-NP OVA- Saline OVA-PF-HA
Lung weight (g) 0.382 0.048 0.327 0.022 0.704 0.171*
yy 0.684 0.029
y 0.462 0.05 0.478 0.095
Leucocyte (  10
5cells) 17.9 1.7 17.39 1.68 119 29.5***
yyy 98.5 2.4**
yy 55.2 4.2
zzz## 21.9 3.39
zz##
Eosinophil (cells/ml) 4.43 1.604 2.683 0.3286 41.67 3.14***
yyy 40.2 0.57***
yyy 12.9 0.99**
yyzzz### 16.7 2.687**
yyzzz###
Values are mean SEM.
*indicates significantly different versus Normal (P<0.05); **(P<0.01); ***(P<0.001);
yversus Normal-PF-HA (P<0.05);
yy(P<0.01);
yyy(P<0.001);
zzversus OVA-control (P<0.01);
zzz(P<0.001);
##versus OVA-NP (P<0.01);
###(P<0.001).
Figure 2. Photomicrographs of BALF cytospins. The BALF from the OVA-control group had a markedly higher number of eosinophils.
BALF from the OVA-PF-HA group exhibited a significantly lower number of eosinophils (arrows) than the OVA-control, OVA-NP and OVA-saline
groups.
Figure 3. Histological analysis of mouse lung sections. Mouse lung sections (6 mm) were stained with Masson’s trichrome. Lung tissue
from the OVA-PF-HA mouse group showed fewer eosinophils and less collagen accumulation than the OVA-control, OVA-NP and OVA-saline
groups.
82 Anti-asthmatic effect of PF-HAin the lung also increased as a result of OVA-exposure
and was reduced remarkably by PF-HA. NP and saline
injection at ST36 also reduced cell numbers compared to
the OVA-control group, but less effectively (Fig. 4).
IgE and Th2 Cytokines in BALF and Serum Lowered
The levels of IgE, IL-4 and IL-5 in BALF and the levels
of IL-4, IL-5 and IL-13 in the serum were measured
using ELISA. These cytokines and IgE levels were
increased remarkably by OVA-exposure and reduced
significantly by PF-HA. NP and saline injection at
ST36 also reduced these levels, but less effectively
(Table 2).
mRNA Expression of Inflammatory Cytokines Lessened
The mRNA expression levels of TNF-a, IL-4, IL-5 and
IL-13 in the lung were analyzed by RT-PCR. Expression
increased remarkably after OVA exposure. PF-HA
administration at ST36 remarkably reduced mRNA
expression of these cytokines (Fig. 5).
Discussion
In Oriental medicine, acupuncture and herbs are widely
used to treat bronchial asthma (11,13–16), theoretically
by clearing the pathogenic factors and reinforcing the
body’s resistance (immune system; 8). We combined
acupuncture with herbal treatment, to achieve herbal
acupuncture. PF was used for the herbal treatment, and
acupoint ST36 was selected for the acupuncture treat-
ment. According to Oriental medical theory, PF enters
the lung meridian and arrests coughing and wheezing.
ST36 is on the foot Yangming stomach meridian. This
acupoint is known to strengthen the vital energy (‘qi’ in
Oriental medical terminology). The ‘vital energy’ here
means not only stomach qi, even though this acupoint
belongs to the stomach meridian, but also the general
qi in the whole body. For this reason, ST36 is used to
treat various diseases in different parts of the body or
general symptoms in the whole body, including deficiency
and weakness (8,9,17,18). We hypothesized that ST36
could strengthen the general immune energy as well as
lung qi in the case of bronchial asthma. To investigate the
effect of PF-HA at ST36 on allergic bronchial asthma, we
used the OVA-induced asthmatic mouse model (12).
PF-HA at ST36 reduced the lung weight of OVA-
induced asthmatic mice, suggesting it may inhibit
asthmatic lung edema and cellular infiltration into the
lungs (Table 1). The cellular infiltrate that characterizes
asthma consists of mononuclear cells and eosinophils.
The ability to control leukocyte infiltration into the lungs
is viewed as the key to regulating disease severity (19).
PF-HA at ST36 reduced the total number of leukocytes
and eosinophils in the BALF of OVA-induced asthmatic
mice (Table 1). In addition, photomicrographs of the
BALF and histological analysis of lung tissue showed
that PF-HA at ST36 inhibited eosinophil infiltration and
Figure 4. Populations of CD11b+, CCR3+, CD4+ and CD3e+/
CD69+ cells in lungs. The populations of CD11b+, CCR3+, CD4+
and CD3e+/CD69+ cells in lungs were counted using a flow
cytometer. One sample from each group was analyzed. CD11b+,
CCR3+, CD4+ and CD3e+/CD69+ cell counts were markedly lower
in the OVA-PF-HA group than in the OVA-control, OVA-NP and
OVA-saline groups.
Table 2. Effect of PF-HA at ST36 on cytokine levels in BALF and serum
Normal Normal-PF-HA OVA-Control OVA-NP OVA-Saline OVA-PF-HA
BALF
IgE 0.098 0.017 0.105 0.016 0.724 0.151***
yyy 0.62 0.132**
yy 0.234 0.029
zz## 0.156 0.043
zz##
IL-4 0.069 0.008 0.105 0.009 0.217 0.097* 0.129 0.03 0.2885 0.01**
yy# 0.084 0.005
xx
IL-5 0.164 0.022 0.153 0.002 0.358 0.032***
yyy 0.314 0.03**
yy 0.241 0.03*
yzz# 0.176 0.011
zzz##x
Serum
IL-4 0.05 0.006 0.052 0.018 0.312 0.025***
yyy 0.171 0.048**
yyzz 0.08 0.006
zzz# 0.05 0.002
zzz##
IL-5 0.191 0.053 0.186 0.006 1.026 0.154*
y 1.027 0.101*
y 0.379 0.06 0.327 0.037
IL-13 0.390 0.024 0.471 0.02 0.460 0.091**
yy 0.724 0.049**
y 0.682 0.108* 0.327 0.019
zz##xx
Cytokine levels were determined by measuring absorbance at 450nm. Values represent mean SEM.
*indicates significantly different versus Normal (P<0.05); **(P<0.01); ***(P<0.001);
yversus Normal-PF-HA (P<0.05);
yy(P<0.01);
yyy(P<0.001);
zzversus OVA-control (P<0.01);
zzz(P<0.001);
##versus OVA-NP (P<0.01);
###(P<0.001).
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these results, we infer that PF-HA may have therapeutic
activity against airway obstruction and eosinophilic
inflammation in allergic asthma via inhibiting cellular
infiltration and collagen accumulation in the lungs.
Previous studies have suggested that CCR3 is involved
in the activation and degranulation of eosinophils, as well
as in the primary migration of eosinophils (19,20).
In addition, CCR3 is believed to be an important target
in the treatment of eosinophilic inflammation (20). In our
investigation, CCR3+ cells in the mouse lung were
reduced remarkably by PF-HA at ST36, suggesting it
may be effective in controlling the activation, degranula-
tion and migration of eosinophils in allergic asthma
(Fig. 4). We also observed that the number of CD11b+
cells and mRNA expression of TNF-a in asthmatic lungs
were markedly reduced by PF-HA at ST36 (Figs 4
and 5). Based on these results, we speculate that PF-HA
may have an anti-inflammatory effect on allergic asthma
via inhibiting leukocyte migration into the lungs and
suppressing eosinophil activation and degranulation.
Asthma is generally regarded as a T-cell mediated
disease. Allergens cause the differentiation of naive
T- cells into Th2 cells, which then secrete cytokines
such as IL-4, IL-5 and IL-13 (3). IL-4, which is pivotal in
the pathogenesis of allergic disorders, acts on B cells to
facilitate IgE production (3,21). Increased IgE production
in response to common environmental antigens is the
hallmark of atopic diseases such as bronchial asthma
(22). IL-4 also induces the rolling and adhesion of
circulating eosinophils to endothelial cells. Therefore,
inhibitors of the IL-4 signaling pathway have been
suggested as therapeutic targets (23,24).
Our results showed that PF-HA at ST36 significantly
decreased IL-4 in BALF and serum, and mRNA
expression of IL-4 in the lung (Table 2, Fig. 5). The
lung histology observed here (Fig. 3) showed that PF-HA
at ST36 reduced eosinophils in lung tissue, and we
speculate that the reduction in eosinophils may be due to
a decrease in IL-4 by PF-HA at ST36. Based on these
results, it is inferred that PF-HA may have an anti-
allergic effect on allergic bronchial asthma by suppressing
IL-4 secretion and, in consequence, inhibiting IgE secre-
tion from B cells. Further, reduced IL-4 may reduce
eosinophil infiltration into the lungs by reducing the
adhesion of circulating eosinophils to endothelial cells.
IL-5 is a Th2-type cytokine that promotes the recruit-
ment and activation of eosinophils. IL-5 stimulates the
release of chemical mediators from eosinophils (25).
Airway eosinophilic inflammation is one of the char-
acteristics of bronchial allergic asthma. Therefore, IL-5
has been implicated in the pathogenesis of allergic
diseases (26,27), and many investigations focused on
IL-5 as a viable target for the treatment of asthma and
allergic diseases (28–30). In this study, PF-HA at ST36
significantly reduced IL-5 in BALF and serum, as well
as mRNA expression of IL-5 in the lung. As mentioned
earlier, PF-HA at ST36 reduced eosinophil infiltra-
tion and activation in OVA-induced asthmatic mice.
We speculate that this result may be due to the inhibition
of IL-5 secretion from Th2 cells.
The number of CD4+ cells and CD3e+/CD69+ cells
in asthmatic mouse lungs were remarkably reduced
by PF-HA at ST36 (Fig. 4). Also, Th2 cytokines such
as IL-4, IL-5 and IL-13 were reduced significantly by
PF-HA at ST36. These results indicate that PF-HA may
suppress the excess activity of T- cells and Th2 cytokines,
which are implicated in the pathogenesis of allergic
asthma, and consequently restore the Th1/Th2 imbalance
of the immune system. From these results, we hypothe-
size that PF-HA has an immuno-regulatory function
for Th1 and Th2, and a suppressive effect on excessive
Th2 cytokines. This Th1/Th2 balancing effect may lead
to anti-allergic and anti-inflammatory effects by way of
(i) reducing IL-4 secretion from Th2 cells to decrease
IgE production from B cells and to reduce eosinophil
infiltration into the lungs by inhibiting adhesion of
eosinophils to endothelial cells and (ii) reducing IL-5 to
decrease eosinophil recruitment and activation.
Th2 cytokines such as IL-13, IL-4 and IL-5 and
elevated IgE levels are associated with the development
of airway hyper-reactivity. In particular, IL-13 mediates
airway hyper-responsiveness in allergic lungs (31–33).
Figure 5. mRNA expression of cytokines in the lung. The mRNA
expression of IL-4, IL-5, IL-13 and TNF-a in the lung was analyzed by
RT-PCR. Note that the mRNA expression of IL-4, IL-5 and TNF-a
was lower in the OVA-PF-HA group than in the OVA-control,
OVA-NP and OVA-saline groups. mRNA expression of IL-13 was
significantly lower in the OVA-PF-HA group than in the OVA-NP and
OVA-saline groups.
84 Anti-asthmatic effect of PF-HAHere, PF-HA at ST36 reduced IL-4, IL-5, IL-13 and IgE
levels in the BALF and serum (Table 2). Furthermore,
mRNA expression of these cytokines in the lung was
reduced remarkably by PF-HA at ST36 (Fig. 5). From
these results, we conclude that PF-HA may suppress
airway hyper-responsiveness by reducing these cytokines.
In most of the measurements discussedearlier, the
normal-PF-HA group did not show any considerable
differences from the normal group. This result indicates
that PF-HA does not cause any changes in normal
conditions and, furthermore, it does not interrupt the
homeostasis of healthy subjects.
In our study, NP at ST36 appeared to work in
a positive direction to suppress OVA-induced asthma,
although it was not as effective as PF-HA. This result
suggests that the mechanical stimulation of ST36 has
a beneficial effect on bronchial allergic asthma, even
though it is not as effective as PF-HA at ST36. Saline
injection at ST36 also had positive effects on OVA-
induced asthma in most measurements; however, PF-HA
showed more beneficial effects than saline injections.
Thus, we speculate that PF extract has therapeutic
activity on OVA-induced asthma in addition to the
mechanical stimulation provided by PF-HA. It is regret-
table that we do not have experimental data on PF-HA
at a non-acupoint to compare to the effect of PF-HA
at ST36 because we cannot discuss the role of ST36 based
on our results. This may be investigated in future studies.
In summary, we hypothesize that PF-HA may be
applicable to bronchial allergic asthma to reduce airway
obstruction by inhibiting cellular infiltration and collagen
accumulation in the lung, and to relieve airway hyper-
responsiveness by reducing IL-4, IL-5, IL-13 and IgE.
Our data further suggest that PF-HA has a therapeutic
effect on bronchial allergic asthma by regulating the
immune system (suppressing excess Th2 activity and
rebalancing Th1/Th2 in the immune system) and con-
trolling eosinophilic inflammation in the airway. The
anti-inflammatory effect of PF-HA may result from its
immuno-regulatory effect on Th1 and Th2 activity.
Further study is needed to determine the mechanisms
of action and application to human subjects.
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